ArticleJournal of global oncology2018
Disparities in Breast, Lung, and Cervical Cancer Trials Worldwide.
Article in Journal of global oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial.Chinese medical journal · 2025Trial
- Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 9).Breast (Edinburgh, Scotland) · 2025Review
- Disparities in cancer clinical trials among low- and middle-income countries: A 20-year analysis.Cancer · 2025Article
- Optimizing Recruitment and Retention in Cancer Clinical Trials in Low-Resource Settings: Barriers and Facilitators From Nigerian Provider's Perspectives.JCO global oncology · 2025Article
- Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers.ESMO open · 2024Review
- Conflict of Interest Disclosure in Oncology: Preliminary Insights From the Global ONCOTRUST-1 Cross-Sectional Study.JCO global oncology · 2024Article
- Global Equity in Clinical Trials: An ASCO Policy Statement.JCO global oncology · 2024Article
- Racial disparities in cancer care, an eyeopener for developing better global cancer management strategies.Cancer reports (Hoboken, N.J.) · 2023Review
- Review
- Characterization of Oncology Clinical Trials Using Germline Genetic Data.JAMA network open · 2022Article
- Determinants of Protective Healthcare Services Awareness among Female Syrian Refugees in Turkey.Healthcare (Basel, Switzerland) · 2022Article
- How does academia respond to the burden of infectious and parasitic disease?Health research policy and systems · 2022Article
- Quantifying geographical accessibility to cancer clinical trials in different income landscapes.ESMO open · 2022Article
- Priorities for cancer research in low- and middle-income countries: a global perspective.Nature medicine · 2022Review
- International trends in pulmonary neuroendocrine cancer studies:a scientometric study.Einstein (Sao Paulo, Brazil) · 2022Article
- A multilevel assessment of the social determinants associated with the late stage diagnosis of breast cancer.Scientific reports · 2021Article
- Geographic disparities in access to cancer clinical trials in India.Ecancermedicalscience · 2021Article
- Observational
- Eliminating Cervical Cancer in Mali and Senegal, Two Sub-Saharan Countries: Insights and Optimizing Solutions.Vaccines · 2020Review
- MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study.Therapeutic advances in medical oncology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAs cancer burden has risen worldwide, physicians, patients, and their advocates have become aware that the clinical cancer trial research paradigm is not ubiquitous. Furthermore, the number and characteristics of trials that are registered in low- and middle-income countries (LMICs) compared with that in high-income countries (HICs) are unknown.
methodsWe collected retrospective data on trials for breast, lung, and cervical cancer registered in ClinicalTrials.gov or with the WHO International Clinical Trial Registry Platform between 2010 and 2017. The data were then classified as trials within LMICs or HICs using definitions from the World Bank.
resultsIncluded in these analyses were 6,710 trials, of which 3,164 (47%) were breast cancer trials, 3,283 (49%) were lung cancer trials, and 263 (4%) were cervical cancer trials. There were 1,951 (29%) trials from LMICs and 4,759 (71%) trials from HICs ( P < .001). Although the proportion of phase III trials in HICs versus LMICs was similar (18% v 17%; P = .66), the number of phase I trials in LMICs was significantly lower than that of HICs (20% v 2%; P < .001). For several LMICs with the highest mortality-to-incidence ratios for breast, lung, or cervical cancer, there were no cancer trials registered in the registration data bases searched for this work.
conclusionThere are differences in access to cancer clinical trials in LMICs compared with HICs. Several factors, such as excessive cost and a lack of infrastructure and expertise, may explain these differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.